Skip to content
Peptigraph home

Semaglutide for Liver Health: What the Evidence Shows

What human and animal studies show about Semaglutide for liver health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
305
PubMed records, our ledger
Animal studies
59
PubMed records, our ledger
Studies we summarised
2
with an outcome for liver health

Evidence for liver health

Each row is an outcome related to liver health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for liver health: outcomes in published studies
OutcomeResultStudy typeSource
Steatohepatitis resolutionSteatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide vs 34.3% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
Fibrosis reductionLiver fibrosis was reduced without worsening steatohepatitis in 36.8% on semaglutide vs 22.4% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
NASH resolutionNASH resolved without worsening fibrosis in 59% at 0.4 mg vs 17% on placebo.Human RCTn = 320The New England journal of medicine 2021, PMID 33185364
Fibrosis stage improvementFibrosis improved in 43% at 0.4 mg vs 33% on placebo, not a significant difference (P = 0.48).Human RCTn = 320The New England journal of medicine 2021, PMID 33185364

PubMed records for Semaglutide and liver health: 305 human, 59 animal (search counts, not studies we reviewed). Grades follow our evidence scale.

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40305708

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Other peptides people research for liver health

TirzepatideBPC-157Kisspeptin-10
All peptides for liver health, compared

Common questions

Does Semaglutide help with liver health?

The strongest study we summarise for liver health is human rct evidence, across 2 studies with an outcome for liver health. A trial result is not an approval; see the legal status.

Is Semaglutide approved for liver health?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for liver health?

There is no single answer. Our liver health overview compares each candidate by evidence grade and legal status rather than by popularity.

More on Semaglutide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  2. 2A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.The New England journal of medicine · 2021PMID 33185364Accessed 2 Oct 2026

Found an error? Report a correction.